AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-MycB-cell lymphomain vivo
| Autor: | Jake Shortt, Richard B. Pearson, Ross D. Hannan, Pui Yee Ng, Jennifer R. Devlin, Ricky W. Johnstone, Carleen Cullinane, Katherine M. Hannan, Megan J. Bywater, Grant A. McArthur |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Lymphoma
B-Cell Transcription Genetic Blotting Western Ribosome biogenesis Apoptosis mTORC1 Biology Real-Time Polymerase Chain Reaction medicine.disease_cause Biochemistry Proto-Oncogene Proteins c-myc Mice Phosphatidylinositol 3-Kinases Transcription (biology) Cell Line Tumor medicine Animals Humans RNA Messenger B-cell lymphoma Molecular Biology Protein kinase B PI3K/AKT/mTOR pathway Cell Proliferation Dromaiidae Reverse Transcriptase Polymerase Chain Reaction Cell Biology medicine.disease Lymphoma Mice Inbred C57BL RNA Ribosomal Disease Progression Cancer research Carcinogenesis Heterocyclic Compounds 3-Ring Proto-Oncogene Proteins c-akt Signal Transduction |
| Zdroj: | FEBS Journal. 280:5307-5316 |
| ISSN: | 1742-464X |
| DOI: | 10.1111/febs.12135 |
| Popis: | The dysregulation of PI3K/AKT/mTORC1 signalling and/or hyperactivation of MYC are observed in a high proportion of human cancers, and together they form a 'super signalling' network mediating malignancy. A fundamental downstream action of this signalling network is up-regulation of ribosome biogenesis and subsequent alterations in the patterns of translation and increased protein synthesis, which are thought to be critical for AKT/MYC-driven oncogenesis. We have demonstrated that AKT and MYC cooperate to drive ribosomal DNA (rDNA) transcription and ribosome biogenesis, with AKT being essential for rDNA transcription and in vitro survival of lymphoma cells isolated from a MYC-driven model of B-cell lymphoma (Eμ-Myc) [Chan JC et al., (2011) Science Signalling 4, ra56]. Here we show that the allosteric AKT inhibitor MK-2206 rapidly and potently antagonizes rDNA transcription in Eμ-Myc B-cell lymphomas in vivo, and this is associated with a rapid reduction in indicators of disease burden, including spleen weight and the abundance of tumour cells in both the circulation and lymph nodes. Extended treatment of tumour-bearing mice with MK-2206 resulted in a significant delay in disease progression, associated with increased B-cell lymphoma apoptosis. Our findings suggest that malignant diseases characterized by unrestrained ribosome biogenesis may be vulnerable to therapeutic strategies that target the PI3K/AKT/mTORC1/MYC growth control network. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |